A new clinical trial involving goserelin, marketed as Zoladex, was listed with a status update dated September 9, 2026. The study, registered as NCT07310420, is titled "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer."
The trial is currently in Phase 1 and its status is listed as recruiting. It is designed to evaluate ovarian suppression in premenopausal women with hormone receptor positive breast cancer, spanning both early-stage and advanced disease presentations, following administration of the subcutaneous 10.8 mg formulation of Zoladex.
No results have been posted for this trial as of the listed date. The study record does not include outcome data, efficacy findings, or safety conclusions at this stage, and none should be inferred from its recruiting status. Further details on trial design, eligibility, and endpoints are available through the official registration.
Readers interested in background on this compound can consult the goserelin overview for additional context.